Summit Therapeutics Sells Phase III Antibiotic Ridinilazole to AI-Native Biossil in Deal Worth Up to $104.5 Million
核心洞察
Summit Therapeutics has signed an agreement to sell its Phase III precision antibiotic ridinilazole to Toronto-based Biossil, Inc. (搜索), an AI-native biopharma company focused on life-threatening indications with urgent unmet needs.
Ridinilazole previously demonstrated a higher observed Sustained Clinical Response rate than vancomycin in the Phase III Ri-CoDIFy study for C. difficile infection but did not meet the primary endpoint for superiority.
Summit will receive $500,000 upfront and up to $104.5 million in regulatory and commercial milestones, plus tiered royalties on net sales, while refocusing on its core oncology strategy.
Summit Therapeutics Inc. (NASDAQ: SMMT) announced on July 14, 2026, that it has signed an agreement with Toronto-based Biossil, Inc. (搜索) for the sale of ridinilazole, an investigational Phase III precision antibiotic. The divestiture allows Summit to sharpen its focus on its core oncology pipeline, particularly the development of ivonescimab, while placing ridinilazole in the hands of an AI-native drug development company committed to advancing late-stage programs in life-threatening indications.
Under the terms of the agreement, Summit will receive $500,000 upfront and is eligible for up to $104.5 million in regulatory and commercial milestone payments, in addition to tiered royalties on net sales. The transaction transfers full ownership of ridinilazole to Biossil, which plans to continue the clinical development of the asset.
Ridinilazole and the Ri-CoDIFy Phase III Study
Ridinilazole was previously evaluated in Summit's Phase III Ri-CoDIFy study, a randomized, double-blind trial comparing the investigational antibiotic against vancomycin — the current standard of care — for the treatment of Clostridioides difficile infection (搜索) (CDI). The study showed that ridinilazole resulted in a higher observed Sustained Clinical Response (SCR) rate than vancomycin but did not meet the study's primary endpoint for superiority within the established time boundaries. SCR is defined as Clinical Response of the treated episode of CDI and no recurrence of the infection through 30 days after the end of treatment.
These results were initially announced by Summit in December 2021 and subsequently published in the journal Clinical Infectious Diseases. Beyond the primary endpoint, the Ri-CoDIFy study and earlier-stage clinical trials demonstrated ridinilazole's ability to spare the gut microbiome compared to vancomycin — a property believed to influence recurrence of CDI.
"Ridinilazole has long represented a scientifically differentiated approach to addressing Clostridioides difficile infection (搜索), a serious disease that continues to place a substantial burden on patients, caregivers, and healthcare systems," said Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit. Duggan highlighted that exploratory data from previous clinical trials, which require further study, demonstrated numerical differences favoring ridinilazole versus vancomycin, including microbiome preservation, lower recurrence rates, reduced toxin production, dosing convenience, and tolerance.
Biossil's AI-Native Approach
Biossil, Inc. (搜索) describes itself as an AI-native drug development company with teams in Toronto and Boston, advancing a pipeline of late-stage, first-in-class candidates for heterogeneous and life-threatening diseases. The company integrates proprietary artificial intelligence with deep clinical and translational expertise, supported by partnerships with leading academic medical centers and research hospitals.
"Introduction of novel, microbiome-sparing antibiotics has lagged the growing global need," said Alexander Mosa, MD, PhD, CSO and Chair of Biossil. "Recurrent C. difficile infection, selection of antibiotic-resistant genes, and gut dysbiosis are common, burdensome, and in need of new approaches. We thank Summit for entrusting us with continued development of ridinilazole, and we will advance this program with urgency and focus."
The Burden of C. difficile Infection
Clostridioides difficile infection (搜索) is a bacterial infection of the colon that produces toxins causing inflammation, severe watery diarrhea, painful abdominal cramping, nausea, fever, and dehydration. CDI can progress to more serious complications including bowel perforation, sepsis, and death. It represents a serious healthcare issue in hospitals, long-term care facilities, and the wider community.
According to the Peggy Lillis Foundation, C. difficile causes nearly 500,000 infections in the United States each year and contributes to more than 29,000 deaths annually, making it the most common healthcare-associated infection. CDC surveillance data from 2024 Emerging Infections Program sites report an incidence of 124.4 cases per 100,000 people, with most cases associated with recent antibiotic exposure. Recent peer-reviewed analyses further underscore CDI's ongoing economic burden, including substantial excess healthcare costs among commercially insured adults and high per-patient annual direct medical costs associated with recurrent CDI.
Ridinilazole is not currently approved by any regulatory authority, and its safety and efficacy have not been evaluated by the United States Food and Drug Administration or other regulatory bodies.